PITTSBURGH - Predictive Oncology Inc. (NASDAQ: NASDAQ:POAI), a company focused on AI-driven drug discovery and biologics, has shared results from a retrospective study indicating that its AI and machine learning (ML) capabilities might improve survival outcome predictions for ovarian cancer patients over traditional clinical data. The study, conducted in collaboration with UPMC Magee-Womens Hospital, will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting scheduled for May 31-June 4, 2024, in Chicago, IL.
The research aimed to develop ML models that could more accurately forecast short-term (two-year) and long-term (five-year) survival outcomes among patients with high-grade serous ovarian cancer, a form of cancer that is difficult to treat due to often being symptomless in early stages. According to Dr. Robert Edwards from Magee-Womens Hospital, nearly 80% of patients relapse within two years, and only 20% are long-term survivors. The study's findings suggest that ML could assist in clinical management and tailor treatments to individual patients.
Dr. Brian Christopher Orr will present the study findings at the ASCO meeting. The study analyzed data and tumor specimens from 2010-2016, using patient data, whole exome and transcriptome sequencing, drug response profiles, and digital pathology profiles to train 160 multi-omic ML models. The models' performance was measured using the AUROC metric, with scores above 0.5 indicating higher predictive potential.
Out of the 160 models, seven demonstrated high accuracy for two-year survival, and 13 for five-year survival predictions. The results showed that multi-omic input features led to better predictions than clinical data alone, with top-performing models outperforming any single feature set.
Predictive Oncology believes these results support the continued development of ML models for clinical use and the potential for identifying unique biomarkers for novel cancer therapeutics. The company, with its extensive biobank and AI platform PEDAL, which predicts drug responses with 92% accuracy, positions itself as a leader in the field of AI-based drug discovery.
This information is based on a press release statement from Predictive Oncology Inc.
InvestingPro Insights
Predictive Oncology Inc. (NASDAQ: POAI) has recently captured the attention of the medical community with its promising use of AI in cancer treatment predictions. From an investor's perspective, the company presents a mixed financial landscape.
InvestingPro data indicates that Predictive Oncology holds a market capitalization of $6.44M USD, reflecting a relatively small player within the biotech industry. Despite this, the company has demonstrated notable revenue growth, with figures from the last twelve months as of Q1 2024 showing an impressive increase of 36.98%. This is further highlighted by a quarterly revenue growth of 74.93% in Q1 2024, which may interest investors looking for companies with strong growth trajectories.
On the other hand, a significant Operating Income Margin of -749.71% shows the company is facing challenges in converting its revenues into operating income. Additionally, the P/E Ratio stands at -0.43, and the adjusted P/E Ratio for the last twelve months as of Q1 2024 is -0.44, suggesting that the market has concerns about the company's current profitability.
InvestingPro Tips for Predictive Oncology underscore the dichotomy of its financial health. On a positive note, the company holds more cash than debt on its balance sheet, which provides a cushion for operational needs and potential investments. Moreover, analysts anticipate sales growth in the current year, aligning with the reported revenue increases. However, it's important to note that the company is not currently profitable, as evidenced by the last twelve months, and it does not pay a dividend to shareholders, which could be a drawback for income-focused investors.
For those considering an investment in Predictive Oncology, it's worth exploring the additional 16 InvestingPro Tips available on the platform, which provide deeper insights into the company's financials and market performance. To gain access to these valuable tips, visit https://www.investing.com/pro/POAI and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. These tips could provide a more comprehensive understanding of the company's potential and investment risks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.